Format

Send to

Choose Destination
Cancers (Basel). 2019 May 22;11(5). pii: E707. doi: 10.3390/cancers11050707.

NF1 Patients Receiving Breast Cancer Screening: Insights from The Ontario High Risk Breast Screening Program.

Author information

1
Program for Genetics and Genome Biology, Hospital for Sick Children, Toronto, ON M5G 1X8, Canada. nika.maani@sickkids.ca.
2
Familial Breast and Ovarian Cancer Clinic, Princess Margaret Hospital Cancer Centre, Toronto, ON M5G 2C1, Canada. nika.maani@sickkids.ca.
3
Department of Molecular Genetics, University of Toronto, Toronto, ON M5S 1A8, Canada. nika.maani@sickkids.ca.
4
Average and High-Risk Ontario Breast Screening Program, Princess Margaret Cancer Centre, Toronto, ON M5G 2C1, Canada. shelley.westergard@uhn.ca.
5
Department of Molecular Genetics, University of Toronto, Toronto, ON M5S 1A8, Canada. joannay.yang@mail.utoronto.ca.
6
Department of Medical Imaging, University of Toronto, Toronto, ON M5T 1W7, Canada. anabel.scaranelo@uhn.ca.
7
Joint Department of Medical Imaging, Division of Breast Imaging, Princess Margaret Cancer Centre, Sinai Health System and Women's College Hospital, Toronto, ON M5G 2C1 and M5S 1B2, Canada. anabel.scaranelo@uhn.ca.
8
Prenatal Diagnosis and Medical Genetics Program, Mount Sinai Hospital, Toronto, ON M5G 1X5, Canada. stephanie.telesca@sinaihealthsystem.ca.
9
Familial Breast and Ovarian Cancer Clinic, Princess Margaret Hospital Cancer Centre, Toronto, ON M5G 2C1, Canada. emily.thain@uhn.ca.
10
University Health Network, Toronto, ON M5GC4, Canada. nathan.schachter@uhn.ca.
11
Familial Breast and Ovarian Cancer Clinic, Princess Margaret Hospital Cancer Centre, Toronto, ON M5G 2C1, Canada. jeanna.mccuaig@uhn.ca.
12
Department of Molecular Genetics, University of Toronto, Toronto, ON M5S 1A8, Canada. jeanna.mccuaig@uhn.ca.
13
Familial Breast and Ovarian Cancer Clinic, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON M5G 2C1, Canada. raymond.kim@uhn.ca.
14
Department of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada. raymond.kim@uhn.ca.

Abstract

Neurofibromatosis Type I (NF1) is caused by variants in neurofibromin (NF1). NF1 predisposes to a variety of benign and malignant tumor types, including breast cancer. Women with NF1 <50 years of age possess an up to five-fold increased risk of developing breast cancer compared with the general population. Impaired emotional functioning is reported as a comorbidity that may influence the participation of NF1 patients in regular clinical surveillance despite their increased risk of breast and other cancers. Despite emphasis on breast cancer surveillance in women with NF1, the uptake and feasibility of high-risk screening programs in this population remains unclear. A retrospective chart review between 2014-2018 of female NF1 patients seen at the Elizabeth Raab Neurofibromatosis Clinic (ERNC) in Ontario was conducted to examine the uptake of high-risk breast cancer screening, radiologic findings, and breast cancer characteristics. 61 women with pathogenic variants in NF1 enrolled in the high-risk Ontario breast screening program (HR-OBSP); 95% completed at least one high-risk breast screening modality, and four were diagnosed with invasive breast cancer. Our findings support the integration of a formal breast screening programs in clinical management of NF1 patients.

KEYWORDS:

breast cancer; high-risk screening; neurofibromatosis type I; screening uptake

Supplemental Content

Full text links

Icon for Multidisciplinary Digital Publishing Institute (MDPI) Icon for PubMed Central
Loading ...
Support Center